ClinicalTrials.Veeva

Menu

Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix

Lilly logo

Lilly

Status and phase

Completed
Phase 3

Conditions

Cancer of Cervix

Treatments

Radiation: Brachytherapy
Drug: Gemcitabine
Radiation: Pelvic radiation
Drug: Cisplatin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00191100
B9E-MC-JHQS
4015

Details and patient eligibility

About

The purpose of this study is to compare the effectiveness of two methods of treating cancer of the cervix. Half the patients will receive gemcitabine plus cisplatin while undergoing radiation therapy, followed by adjuvant gemcitabine and cisplatin and the other half will receive cisplatin along with radiation therapy without adjuvant therapy.

Enrollment

515 patients

Sex

Female

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • diagnosed with cancer of cervix
  • tumor that can be measured
  • no previous treatment with chemotherapy or radiation for this cancer
  • Karnofsky Performance Status Score >=70
  • able to give written consent
  • willing and able to participate in the study, both during the active treatment and the follow-up period.

Exclusion criteria

  • impairment such as hearing loss from prior cisplatin therapy
  • damage to nerves such as being unable to distinguish hot and cold to touch
  • used other experimental medication in past 30 days
  • lab test results are not within the limits required for this study
  • pregnancy or breast-feeding or possibility of becoming pregnant during this study and not using an approved method of birth control.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

515 participants in 2 patient groups

1
Experimental group
Description:
Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Gemcitabine 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks Brachytherapy, 30-35 Gy over 1 week Two week rest period with no chemotherapy or radiation Cisplatin, 50 mg/m2, intravenous (IV), day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
Treatment:
Drug: Cisplatin
Radiation: Brachytherapy
Drug: Gemcitabine
Radiation: Pelvic radiation
2
Active Comparator group
Description:
Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks Brachytherapy, 30-35 Gy over 1 week
Treatment:
Drug: Cisplatin
Radiation: Brachytherapy
Radiation: Pelvic radiation

Trial contacts and locations

7

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems